These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 37973912)
21. TERT promoter mutated WHO grades II and III gliomas are located preferentially in the frontal lobe and avoid the midline. Sun ZL; Chan AK; Chen LC; Tang C; Zhang ZY; Ding XJ; Wang Y; Sun CR; Ng HK; Yao Y; Zhou LF Int J Clin Exp Pathol; 2015; 8(9):11485-94. PubMed ID: 26617880 [TBL] [Abstract][Full Text] [Related]
22. cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV". Brat DJ; Aldape K; Colman H; Holland EC; Louis DN; Jenkins RB; Kleinschmidt-DeMasters BK; Perry A; Reifenberger G; Stupp R; von Deimling A; Weller M Acta Neuropathol; 2018 Nov; 136(5):805-810. PubMed ID: 30259105 [No Abstract] [Full Text] [Related]
23. IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification. Berzero G; Di Stefano AL; Ronchi S; Bielle F; Villa C; Guillerm E; Capelle L; Mathon B; Laurenge A; Giry M; Schmitt Y; Marie Y; Idbaih A; Hoang-Xuan K; Delattre JY; Mokhtari K; Sanson M Neuro Oncol; 2021 Jun; 23(6):955-966. PubMed ID: 33173941 [TBL] [Abstract][Full Text] [Related]
24. Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma. Satomi K; Ohno M; Matsushita Y; Takahashi M; Miyakita Y; Narita Y; Ichimura K; Yoshida A Mod Pathol; 2021 Apr; 34(4):688-700. PubMed ID: 33077924 [TBL] [Abstract][Full Text] [Related]
25. Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma. Bale TA; Jordan JT; Rapalino O; Ramamurthy N; Jessop N; DeWitt JC; Nardi V; Alvarez MM; Frosch M; Batchelor TT; Louis DN; Iafrate AJ; Cahill DP; Lennerz JK Neuro Oncol; 2019 May; 21(5):596-605. PubMed ID: 30496526 [TBL] [Abstract][Full Text] [Related]
26. Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation. Ferreira MSV; Sørensen MD; Pusch S; Beier D; Bouillon AS; Kristensen BW; Brümmendorf TH; Beier CP; Beier F J Neurooncol; 2020 Mar; 147(1):1-14. PubMed ID: 31960234 [TBL] [Abstract][Full Text] [Related]
27. Predicting TERT promoter mutation status using Yamashita K; Hatae R; Kikuchi K; Kuga D; Hata N; Yamamoto H; Obara M; Yoshimoto K; Ishigami K; Togao O Neuroradiology; 2023 Aug; 65(8):1205-1213. PubMed ID: 37308686 [TBL] [Abstract][Full Text] [Related]
28. Beyond the World Health Organization classification of central nervous system tumors 2016: what are the new developments for gliomas from a clinician's perspective? Weller M; Reifenberger G Curr Opin Neurol; 2020 Dec; 33(6):701-706. PubMed ID: 33177376 [TBL] [Abstract][Full Text] [Related]
29. Correlation between IDH, ATRX, and TERT promoter mutations in glioma. Ohba S; Kuwahara K; Yamada S; Abe M; Hirose Y Brain Tumor Pathol; 2020 Apr; 37(2):33-40. PubMed ID: 32227259 [TBL] [Abstract][Full Text] [Related]
30. cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Brat DJ; Aldape K; Colman H; Figrarella-Branger D; Fuller GN; Giannini C; Holland EC; Jenkins RB; Kleinschmidt-DeMasters B; Komori T; Kros JM; Louis DN; McLean C; Perry A; Reifenberger G; Sarkar C; Stupp R; van den Bent MJ; von Deimling A; Weller M Acta Neuropathol; 2020 Mar; 139(3):603-608. PubMed ID: 31996992 [No Abstract] [Full Text] [Related]
31. Clinical implications of molecular analysis in diffuse glioma stratification. Mizoguchi M; Hata N; Kuga D; Hatae R; Akagi Y; Sangatsuda Y; Fujioka Y; Takigawa K; Funakoshi Y; Suzuki SO; Iwaki T Brain Tumor Pathol; 2021 Jul; 38(3):210-217. PubMed ID: 34268651 [TBL] [Abstract][Full Text] [Related]
32. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Shirahata M; Ono T; Stichel D; Schrimpf D; Reuss DE; Sahm F; Koelsche C; Wefers A; Reinhardt A; Huang K; Sievers P; Shimizu H; Nanjo H; Kobayashi Y; Miyake Y; Suzuki T; Adachi JI; Mishima K; Sasaki A; Nishikawa R; Bewerunge-Hudler M; Ryzhova M; Absalyamova O; Golanov A; Sinn P; Platten M; Jungk C; Winkler F; Wick A; Hänggi D; Unterberg A; Pfister SM; Jones DTW; van den Bent M; Hegi M; French P; Baumert BG; Stupp R; Gorlia T; Weller M; Capper D; Korshunov A; Herold-Mende C; Wick W; Louis DN; von Deimling A Acta Neuropathol; 2018 Jul; 136(1):153-166. PubMed ID: 29687258 [TBL] [Abstract][Full Text] [Related]
33. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Reuss DE; Sahm F; Schrimpf D; Wiestler B; Capper D; Koelsche C; Schweizer L; Korshunov A; Jones DT; Hovestadt V; Mittelbronn M; Schittenhelm J; Herold-Mende C; Unterberg A; Platten M; Weller M; Wick W; Pfister SM; von Deimling A Acta Neuropathol; 2015 Jan; 129(1):133-46. PubMed ID: 25427834 [TBL] [Abstract][Full Text] [Related]
34. Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors. Malzkorn B; Reifenberger G Pathologe; 2019 Jun; 40(Suppl 1):9-17. PubMed ID: 31025086 [TBL] [Abstract][Full Text] [Related]
35. DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status. Cohen A; Sato M; Aldape K; Mason CC; Alfaro-Munoz K; Heathcock L; South ST; Abegglen LM; Schiffman JD; Colman H Acta Neuropathol Commun; 2015 Jun; 3():34. PubMed ID: 26091668 [TBL] [Abstract][Full Text] [Related]
36. Radiologic-pathologic association of tumor-like lesions with inflammation in cerebral white matter: Comparison of two cases with distinct clinical outcomes. Shishido-Hara Y; Akazawa K; Takeuchi H; Hirato J; Konishi E; Yamada K; Itoh K; Hashimoto N Neuropathology; 2021 Dec; 41(6):468-475. PubMed ID: 34791710 [TBL] [Abstract][Full Text] [Related]
37. Germline ALK variations are associated with a poor prognosis in glioma and IDH-wildtype glioblastoma. Bu L; Hameed NUF; Luo C; Hong P; Zhou X; Wang S; Wu S J Neurooncol; 2021 Mar; 152(1):27-36. PubMed ID: 33486679 [TBL] [Abstract][Full Text] [Related]
38. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas. Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441 [TBL] [Abstract][Full Text] [Related]
39. Molecular Correlates of Long Survival in IDH-Wildtype Glioblastoma Cohorts. Galbraith K; Kumar A; Abdullah KG; Walker JM; Adams SH; Prior T; Dimentberg R; Henderson FC; Mirchia K; Sathe AA; Viapiano MS; Chin LS; Corona RJ; Hatanpaa KJ; Snuderl M; Xing C; Brem S; Richardson TE J Neuropathol Exp Neurol; 2020 Aug; 79(8):843-854. PubMed ID: 32647886 [TBL] [Abstract][Full Text] [Related]
40. Characteristics of the isocitrate dehydrogenase gene and telomerase reverse transcriptase promoter mutations in gliomas in Chinese patients. Qu CX; Ji HM; Shi XC; Bi H; Zhai LQ; Han DW Brain Behav; 2020 Apr; 10(4):e01583. PubMed ID: 32146731 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]